Trevi Therapeutics, Inc. TRVI Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s accrued expenses?
- Trevi Therapeutics, Inc. (TRVI) reported accrued expenses of $4.58M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Trevi Therapeutics, Inc.'s accrued expenses decreased by 11.4% year-over-year, from $5.17M to $4.58M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Trevi Therapeutics, Inc.'s accrued expenses has grown at a 10.1% compound annual growth rate (CAGR), from $3.43M to $5.53M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.